Louisiana's PACE Task Force studies GLP-1 medicines used for diabetes and weight management, reports its findings, and recommends possible legislation.
The PACE Task Force studies access to GLP-1 medicines and their insurance costs. Its findings are due to legislative insurance committees by February 12, 2027, when the group must end unless it finishes earlier.
The PACE Task Force studies GLP-1 medicines and recommends possible legislation. The five seats cover state insurance, health, and pharmacy officials, a health-plan association representative, and a licensed healthcare provider specializing in hormone disorders and obesity. The Louisiana Department of Insurance provides staff. Members serve without pay, except daily allowances or expense payments available through their own organizations. The legislature recommends study topics, including medicine prices, coverage barriers, and insurance costs. Designee names were due August 1, 2026, and the first meeting was required by September 1, 2026. The group must submit its report and end by February 12, 2027; it ends earlier if its work concludes.
No hearings or votes scheduled.